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Summary The retinoblastoma gene product (RB) contributes to normal cell growth control. One of its
functions is manifest as a block to exit from GI, which is carried out by an RB subspecies which is un- or
underphosphorylated. After RB phosphorylation, a process which occurs towards the end of GI in cycling
cells, the block is lifted allowing a cell to enter S. Here, we review a series of results which speak to the
elements of RB structure which contribute to this activity. Included is its internal colinear protein receptor
domain (i.e. the 'pocket').
The retinoblastoma gene product (RB) is a 928 aa nuclear
protein which is synthesised in a wide variety of mammalian
cells. The absence of a properly functioning RB allele in
several cell types is linked to the appearance of a neoplastic
phenotype. In the hereditary retinoblastoma syndrome, there
is, among affected individuals, an enhanced susceptibility to
multi-focal, invasive lesions of the retina. In these tumour
cells, a functioning RB gene is absent. In both the founding
zygote of these patients and within their normal somatic
cells, only one operating RB allele is present. Given these
findings, it seems fair to argue that RB function normally
helps to protect retinal cells against the development of a
transformed phenotype. RB is, therefore, the product of a
tumour suppressor gene. Indeed, it is widely expressed among
various mammalian cell types, and it likely plays a tumour
suppressor role in both retinal and some non-retinal cells.
RB exists as a differentially phosphorylated set ofpolypep-
tide products of a single gene (Buchkovich et al., 1989; Chen
et al., 1989; DeCaprio et al., 1989; Mihara et al., 1989; Xu et
al., 1989; Ludlow et al., 1990; Decaprio et al., 1992). Its
phosphorylation is cell cycle-dependent, with cells containing
un(der)phosphorylated protein through much of GI and
phosphorylated protein through S, G2, and most of M
(Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al.,
1989; Mihara et al., 1989; Ludlow et al., 1990). In cycling
cells, RB phosphorylation begins toward the end of GI, and
persists through S and G2 (DeCaprio et al., 1992). Phos-
phorylated RB is enzymatically dephosphorylated in M,
beginning at anaphase (Ludlow et al., 1990; Ludlow et al.,
1992). By the time cells are established in the next G1, it
appears that they again contain largely unphosphorylated RB
(Ludlow et al., 1993).
RB forms complexes with certain transforming proteins of
three different DNA tumour virus species. Adenovirus EIA,
papovaviral large T antigen, and the E7 product of the
transforming strains of human papilloma virus all form
stable complexes with RB. All do so through the action of a
short (- 12 aa), colinear peptide sequence (the 'yellow block'
sequence) imbedded within each protein structure (DeCaprio
et al., 1988; Whyte et al., 1988; Dyson et al., 1989a; Whyte et
al., 1989). All of these 'yellow block' elements conform to a
tight consensus sequence which describes them, and peptide
replicas of each will bind effectively to RB, competing with
each of the viral proteins in the process (Kaelin et al.,
1990).
Genetic analysis indicates that ElA, T, or E7 binding to
RB contributes to the transforming function of each of these
proteins. Indeed, it was further concluded that when each of
them binds to RB, it down modulates or inhibits one or
more aspects of the growth regulatory function of RB
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(DeCaprio et al., 1988; Whyte et al., 1989; Dyson, 1990).
Also notable is the fact that T binds only to
un(der)phosphorylated RB and not to its phosphorylated
forms (Ludlow et al., 1989). Since it does not lead to a
redistribution of the relative abundances of these two generic
RB species, it is fair to argue that the un(der)phosphorylated
form of RB carries out those growth regulatory functions
which T perturbs. Similarly the phosphorylated forms lack
these particular functions, although it seems likely that they
can perform other RB growth regulating actions. Given this,
it can be argued that the timely phosphorylation of RB near
the end of GI inactivates those aspects of RB growth
regulatory function which T can perturb. Since T is a known
mitogen capable of driving a Gl arrested cell into S and RB
is a growth suppressing element (Mueller et al., 1978; Sop-
rano et al., 1983; Huang et al., 1988), we have suggested that
un(der)phosphorylated RB normally operates, at least in
part, by blocking exit from GI and that this block can be
lifted by RB phosphorylation (DeCaprio et al., 1989; Ludlow
et al., 1989; Ludlow et al., 1990).
Within the RB sequence, there is a - 400 aa colinear
segment which, alone, can bind T, ElA, or E7 with roughly
the same affinity as intact RB (Hu et al., 1990; Huang et al.,
1990; Kaelin et al., 1990). We have labelled this segment, the
RB 'pocket', being a large internal protein receptor domain
of the protein. Indeed, the pocket not only contacts viral
transforming proteins, it also binds to a complex set of
cellular proteins. Dissected away from the remainder of the
RB sequence, the 'pocket' can still interact stably with both
the aforementioned viral and cellular proteins (Kaelin et al.,
1991). Since this domain is large and is a prominent site of
naturally occurring mutations in human tumours which inac-
tivate RB function, one obvious question is whether its func-
tion contributes to the growth suppression function of
unphosphorylated RB. In this report, we will review
experiments which attempt to answer this question (Qin et
al., 1992).
Results
Effects ofintroducing RB into the RB-1- cell line, Saos-2
Others had shown previously that introduction of RB into a
number of RB-/- cell lines will arrest cell growth (Huang et
al., 1988; Bookstein et al., 1990; Takahashi et al., 1991). In
Saos-2, a line of human osteogenic sarcoma cells, we found
that this phenotype was joined by the appearance of promi-
nent cellular swelling (Qin et al., 1992) (Figure 1). An
immediate question was whether both sets of phenotypes
were tightly linked to the production of RB and, if so,
whether the same sets of RB sequences were needed to effect
both biological changes. We have not answered these two
questions in full, but do know the following. First, when RB
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Figure 1 SAOS2 cells were transfected and their morphology was analysed by phase-contrast (X400) light microscopy. The
plasmids used for transfection were pCMV, pCMV-RB(379-928), pCMV-RB(379-928; 706F), and pCMV-RB. PCMV contains the
CMV promoter used to drive transcription of linked RB sequences in the other plasmids employed here. The nature of the RB
sequences linked to this promoter in the other three plasmids employed is described in the text and in Figure 4. All plasmids
contain a Neor Marker. Shown are cells transfected 12 days earlier with the plasmids noted under each picture and grown in
G418-containing media. This and all other figures in this paper are represented here with the permission of Genes and
Development (Qin et al., 1992).
was introduced into Saos-2 in the presence of a neoR
marker, there was a dramatic reduction in G418R colony
formation (Qin et al., 1992) (Figure 2). Since no such reduc-
tion was noted in the absence of RB synthesis, this
phenotype could be laid at the doorstep of RB.
The RBpocket must be intactfor growth suppression in these
assays
When various RB mutants were tested in these assays, we
found that the RB 'pocket' was essential to the appearance
of 'big' cells and to the cessation of growth (Qin et al., 1992)
(Figure 2). This was manifest by the failure of the C706-*F
mutant of RB to block colony formation and the appearance
of large cells (Qin et al., 1992) (Figures 2 and 1). Indeed,
when various RB deletion mutants were studied, it became
clear that both the RB pocket and much, if not all, of its
C-terminal 135 aa were essential to suppressing drug-resistant
colony formation (Qin et al., 1992) (Figure 4).
What is the significance offinding that the RBpocket and its
C-terminus are both essential to blocking G418 colony
formation?
The RB pocket can form complexes with at least 8 or more
cellular proteins in vitro (Kaelin et al., 1991), making it
difficult, ab initio, to single out which, if any, of the known
interactions are essential to the RB growth suppression effect.
However, it is also clear that another RB binding protein, the
transcription factor, E2F, can, unlike the others, be assayed
functionally. Although we knew that the pocket contributed
to its binding to RB, it was not clear whether the pocket was
sufficient for this effect (Chittenden et al., 1991). Thus, we
measured the E2F binding activity of a series of RB mutants,
much as we did earlier for their growth suppression effect
(Qin et al., 1992) (Figure 3). In all of this, the main question
was whether there was linkage between the ability of RB to
interact with E2F and its ability to induce cell cycle blockade
in Saos-2. The search for this information was particularly
interesting, because we knew, at the time, that sequences
C-terminal to the RB pocket were not needed for binding to
the cellular proteins previously shown in direct binding
assays to bind RB in vitro (Kaelin et al., 1991). There was
still a chance, however, that E2F binding might depend upon
more than the minimal pocket for binding in the presence of
DNA.
pCMV pCMV-RB (379-928;706F)
pCMV-RB (379-928) pCMV-RB
Figure 2 G418-resistant colony growth by transfected SAOS2
cells. Each culture plate was transfected with 30 .Lg of the DNAs
noted in the figure. Transfected cells were grown in G418-
containing media for 2 weeks. The relevant drug-resistant col-
onies were demonstrated by crystal violet staining.
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Figure 3 RB fusion protein binding to E2F. Assays ofgel retardation were performed with aliquots of a nuclear extract of SAOS2
cells. The probe was a 32P-labelled E2F oligonucleotide from the dihydrofolate reductase (DHFR) promoter. Gel shift-competition
experiments were carried out by introducing a 100-fold molar excess of the unlabelled oligonucleotide competitor which is a replica
of the wild type (WT) or a mutant (MUT) DHFR E2F binding sequence. Lane M contains the products of a control reaction
constituted with a nuclear extract prepared from U937 (human) cells. The arrow denotes the position of a band corresponding to
'free' E2F. Where noted, purified, glutathione S-transferase (GST) or GST-RB fusion proteins were included in the oligonucleotide
binding reactions. Protein/DNA complexes were separated by electrophoresis in 4% non-denaturing polyacrylamide gels. Their
bands were detected by autoradiography. The lane denoted CTL contains a binding reaction constituted with GST-RB (379-928)
and the WT E2F oligonucleotide probe in the absence of any nuclear extract.
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Figure 4 Summary of the relevant data.
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As shown in Figure 4, there was a neat correlation between
the ability of RB to sustain a GI block in Saos-2 and to
form a stable complex with E2F. The latter was determined
in a series of in vitro gel shift assays, in which various
GST-RB fusion proteins were mixed with crude E2F, and the
appropriate RB-E2F supershift complex was sought. The
data clearly show that both the pocket and the C-terminus of
RB are essential to complex formation, as they are to growth
suppression. This didn't prove that complex formation with
E2F is essential to growth suppression. However, it opened
this possibility to futher investigation.
Discussion
These data show that when RB was introduced into at least
one line of cells which lack any RB function, a distinct set of
biological effects was observed. In Saos-2 cells, RB synthesis
is followed by two major events. The cells swell, but remain
attached to the dish. They are also unable to grow, in
keeping with the earlier findings of others (Huang et al.,
1988; Goodrich et al., 1991), who went on to show that the
cell cycle block was in GI. Our aim was to learn whether the
RB pocket is a functional domain in vivo and contributes to
the aforementioned growth suppression effect.
The data show that it is, for the introduction of a single
amino acid substitution in the pocket, which otherwise inac-
tivates its protein binding function, also eliminated the ability
of RB to suppress growth. The surprise in all of this was the
demonstration that the C-terminal segment of the protein
was also important to the growth suppression function.
Indeed, all assays of protein binding had suggested that the
-400 residue minimal 'pocket' domain was sufficient to bind
all of the 35S-cellular protein bands identified in cell free
assays (Kaelin et al., 1991). This implied that there was more
to the protein binding function of RB than the action of its
minimal pocket domain and that this more complex action
could in theory, be part of the answer to how RB suppresses
cell growth in G1.
The results on E2F binding open the possibility that an
interaction of the RB pocket and C-terminus with this pro-
tein(s) contributes to the RB growth suppression function.
Clearly, a correlation of this sort is not proof of this pos-
sibility. However, there is good reason to pursue it further.
E2F is known to play a role in the activation of a number of
genes whose products do the work of the cell cycle-such as
DHFR, c-myc, and cdc2 and others (Thalmeier et al., 1989;
Hiebert et al., 1991; Dalton, 1992: Hamel et al., 1992; Kim et
al., 1992; Means et al., 1992; Moberg et al., 1992). A number
of these genes, when activated, contribute to exit from GI
and passage through S. This being the case, one wonders
whether the interaction of unphosphorylated RB with E2F
contributes to the silencing of one or more of these genes.
Unphosphorylated RB is endowed, we believe, with the GI
exit blocking activity of RB, and others have shown that it
can suppress the action of E2F in vivo. Whether this is a
direct or an indirect effect or both is not known, although
there is reason to suspect that direct complex formation
exists and may contribute to the modulation of E2F action
(Hamel et al., 1992; Hiebert et al., 1992).
Whatever the outcome of the next generation of
experiments, it seems clear that RB has a powerful ability to
modulate cell growth, that its pocket domain contributes to
this action likely through forming specific complexes with
other cellular proteins, and that the elimination of this func-
tion of RB can contribute to the neoplastic phenotype of
common human tumour cells. The challenge now is to
decipher which RB interactions contribute to its growth
modulating function, in which ways E2F complex formation
is linked to RB growth controlling function, and how RB
interactions with a variety of other protein targets are trans-
lated into key growth controlling signals.
Once clearly understood in biochemical terms, it may be
possible to use this and information like it to design rational
strategies for cancer drug development. With the availability
of the right cloned proteins in wild type and appropriately
mutant forms, one should, in principle, be able to design the
rapid screens necessary to detect small molecule compounds
which can selectively perturb individual protein targets
involved in growth control in common human tumour cells.
The ideal compounds in this case would be those which can
only affect growth of cells which have sustained function-
altering mutations in one or more key growth controlling loci
such as RB.
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